A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study Evaluating AVM0703 in Patients With Acute Respiratory Distress Syndrome

Publication date: Jul 29, 2024

This is a randomized, double-blinded, placebo-controlled study of AVM0703 administered as a single intravenous (IV) infusion to patients with moderate or severe immediately life-threatening Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 or influenza (A or B). The study is designed to evaluate the safety, tolerability, and pharmacokinetics of single dose of AVM0703 in these ARDS patients.

Concepts Keywords
Childbearing ARDS
Covid19 COVID19
Immunocompromised Influenza
Influenza

Semantics

Type Source Name
disease MESH Acute Respiratory Distress Syndrome
disease MESH COVID-19
disease MESH influenza
disease VO dose
disease VO age
disease MESH lung collapse
disease MESH Respiratory failure
disease MESH cardiac failure
drug DRUGBANK Oxygen
disease VO effective
disease VO time
disease MESH hypersensitivity
disease MESH duodenal ulcer
disease MESH type 2 diabetes
disease MESH viral infection
disease IDO history
drug DRUGBANK Hepatitis B Vaccine (Recombinant)
disease VO Hepatitis B surface antigen
disease MESH hepatitis B
pathway KEGG Hepatitis B
disease IDO assay
disease MESH hepatitis C
pathway KEGG Hepatitis C
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease VO vaccine
disease MESH Immunocompromised patients
disease VO Human immunodeficiency virus
disease MESH infection
disease MESH chronic renal disease
disease MESH renal failure
disease MESH complications
disease MESH cardiovascular disease
disease MESH myocardial infarction
disease MESH thromboembolism
disease MESH peripheral vascular disease
disease MESH abnormalities
disease MESH cardiac arrhythmia
disease MESH atrial fibrillation
disease MESH left bundle-branch block
disease MESH AV block
disease MESH bradycardia
disease MESH depressive disorder
disease MESH schizophrenia
disease MESH substance abuse
disease VO device
drug DRUGBANK Hydroxychloroquine
drug DRUGBANK Dexamethasone

Original Article

(Visited 2 times, 1 visits today)